Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Alkermes
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Alkermes
-
The
@US_FDA has accepted for review our NDA for ALKS 3831, seeking approval for the treatment of#schizophrenia &#Bipolar1disorder. This is an encouraging step in our pursuit to deliver new medicines to treat serious#mentalhealth disorders: http://bit.ly/2RxWUFl pic.twitter.com/7OklrQRFW7
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“Alkermes R&D capabilities are strong and have evolved significantly over the past several years… The ecosystem is increasingly demanding new medicines based on new biology, and we have been working in that direction for the past several years.”
$ALKS#JPM20pic.twitter.com/3zzXJR1juV
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Join us tomorrow at
#JPMHC20 as CEO Richard Pops takes the stage to share updates on the company’s work to develop innovative medicines for#patients.$ALKSpic.twitter.com/kqjiXyytn6
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Join us live at the J.P. Morgan Healthcare Conference on Wednesday, January 15 at 9:00 a.m. PT (12:00 p.m. ET) to see our CEO Richard Pops as he discusses how we are shaping the future of Alkermes http://bit.ly/2TmJ4qK
$ALKS#JPM20pic.twitter.com/UxIrsYHCly
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Proud to announce that our own distinctive HR leader, Madeline Coffin, has receive the Award of Distinction from
@NEHRLF. Congratulations to Madeline and all the award recipients!https://twitter.com/NEHRLF/status/1204881990056599552 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are heading to London in just a week and are looking forward to attending the
#ScripAwards! Read more about the award ceremony and finalists here: http://bit.ly/2r6FmWn pic.twitter.com/Q68BV8Gxnh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
November is Lung Cancer Awareness Month. Lung cancer is the second most common cancer and the leading cause of cancer death, taking about 156,000 American lives each year. Recognize the risk factors
#lungcancerawarenessmonthpic.twitter.com/BQkeie5NNU
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mark Namchuk, svp, research, pharmaceutical, and non-clinical development discussing his insights on R&D culture and its impact on
#biopharmaceutical#innovation at today’s#STATSummitpic.twitter.com/qqcnt3PJDP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are proud to share that the ALKS 3831 ENLIGHTEN-2 study for schizophrenia was recognized with a “highly commended” accolade for the 2019 Clinical Trial of the Year at the
#LifestarsAwards. Thank you@LSXLeaders for this honor http://bit.ly/2QEREjh pic.twitter.com/DKzF2PfCDg
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congratulations to our excellent HR Leader, Madeline Coffin, for her nomination for an
@NEHRLF 2019 HR Excellence Award! Best of luck to all of the nominees!https://twitter.com/NEHRLF/status/1196441410188304384 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced the submission of a New Drug Application to the
@US_FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder. View our press release to learn more: http://bit.ly/2QAZSsH pic.twitter.com/DbG84Xl3jH
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alkermes News proslijedio/la je Tweet
Congratulations to
@Alkermes and@Rodintx on advancing important research for neurological diseases -- "Alkermes to Acquire Rodin Therapeutics" https://rodintherapeutics.com/press_releases/alkermes-to-acquire-rodin-therapeutics/ …https://twitter.com/aj_rosenberg/status/1196399550937874435 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alkermes News proslijedio/la je Tweet
Very proud of what our team
@Rodintx has accomplished over 4+ years of cutting-edge research in challenging neurological areas with massive unmet need - look forward to continued progress @Alkermeshttps://www.prnewswire.co.uk/news-releases/alkermes-to-acquire-rodin-therapeutics-808518212.html …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alkermes is excited to announce our pending acquisition of
@Rodintx to build on our experience in central nervous system (CNS) diseases and expand our CNS development efforts into a wide range of neurodegenerative disorders. More information:http://bit.ly/354WYk2Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This week, and always, we salute nurse practitioners and the essential role they play in
#patient care.#NPWeekhttps://twitter.com/AANP_NEWS/status/1193528875139174400 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today, we honor Chris, colleague & Marines
#veteran, whose dedication to ppl living with#addiction extends beyond his job & into the community he's deeply connected to. We thank him, & all active duty military & veterans, for their service.#VeteransDay Watch his story:pic.twitter.com/GBS5C4SM5zHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you to all who joined us at
#SITC2019. We are energized more than ever to advance research in oncology.pic.twitter.com/U5P1ZG5dEy
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thanks to everyone who attended our presentation at
#NEICongress. If you missed it, stop by Alkermes Booth 203 to learn about a#2monthLAI treatment for adults with#schizophrenia.pic.twitter.com/U1ec8zZJtr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Right now, Stephen R. Saklad, PharmD, BCPP, is talking about the importance of the
#therapeuticalliance. Come to this live presentation at#NEICongress The Broadmoor, Colorado Hall and learn about a#2monthLAI#schizophrenia treatment for adults.pic.twitter.com/bD2CTmLE1T
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Join the Alkermes product theater at
#NEICongress. Learn about a#2monthLAI for#schizophrenia. Discussing treatment options supports the#therapeuticalliance with patients and care teams. Can’t make it? Visit Alkermes Booth 203 to learn more.#SakladSpeakspic.twitter.com/NWzq5VijqV
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.